Ovid Therapeutics Reports Q3 2026 Financial Results
Ovid Therapeutics reported $161.4 million in cash as of Q3 2026. The company is advancing OV329 to late-stage trials, targeting key epilepsy indications including TSC-associated seizures.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed